Accreditation/
Credit Designation
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Physicians' Education Resource®, LLC designates this live activity for a maximum of 23.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CONTINUING EDUCATION CREDIT (Pharmacists, Nurses, Nurse Practitioners, and Physician Assistants):
You will receive a certificate of attendance for the CME-certified sessions (those designated for AMA/PRA Category 1 Credits™) which may be submitted to state licensing boards for determination of credit reciprocity (conversion to CEUs).
Acknowledgment of Commercial Support
This activity is supported by educational grants from Astellas, AstraZeneca, Boston Biomedical Pharma, Inc., Celgene Corporation, Clovis Oncology, Eisai Inc., Exelixis, Incyte Corporation, Ipsen Biopharmaceuticals, Inc., Lilly, Merck & Co., Inc., Merrimack Pharmaceuticals, Nektar Therapeutics, Novartis Pharmaceuticals Corporation, Novocure, Pharmacyclics, Inc. and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Puma Biotechnology, Taiho Oncology, Inc., and Takeda Oncology.For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
The CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® is wholly owned and operated by PER Events, LLC, an affiliate of Physicians' Education Resource®.
33rd Annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®
 Click here to download brochure |
New York Marriott Marquis
1535 Broadway
New York, NY 10036
Overview
State-of-the-art cancer care continues to evolve due to advances in all aspects of patient care - including diagnosis, and personalized treatment and management. Through the incorporation of novel diagnostics, systemic therapies, molecular targeted therapies, immunotherapies, and other biotechnological strategies into treatment paradigms, patient outcomes continue to improve along the cancer continuum. The annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®, has brought together over 2,000 oncologists, hematologists, radiation oncologists, immunologists, oncology nurses, nurse practitioners, physician assistants, and case managers each year for 32 years, with the aim of educating these disciplines on state-of-the-art treatments across solid and hematologic malignancies and diverse clinical scenarios. At the 33rd Annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®, our outstanding faculty of leading clinical innovators in virtually every tumor subspecialty will continue to provide expert insights on new developments in cancer therapeutics, and provide oncology professionals with the opportunity to learn about new compounds, novel approaches to diagnosis and treatment with currently available agents, ongoing clinical trials, and emerging developments that define current progress aimed at the goal of control and cure of cancer.
Target Audience
This educational program is directed toward oncologists and hematologists interested in the treatment of patients with cancer. Radiotherapists, immunologists, fellows, nurse practitioners, nurses, physician assistants, researchers, case managers, and other health care professionals interested in the treatment of cancer are also invited to attend.
Program Co-Chairs
Edward Ambinder, MDClinical Professor
Medicine, Hematology and Medical Oncology
Clinical Professor, Oncological Sciences
Mount Sinai Hospital
New York, NY
Franco Muggia, MDProfessor, Department of Medicine
NYU Langone Medical Center
New York, NY
Steering Committee
Kimberly L. Blackwell, MD
Medical Oncologist
Duke Cancer Center
Durham, NC
C. Ola Landgren, MD, PhD
Hematologic Oncologist
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY
Jason J. Luke, MD
Medical Oncologist
Assistant Professor of Medicine
University of Chicago Medicine
Chicago, IL
John L. Marshall, MD
Chief, Division of Hematology/Oncology
Georgetown University Hospital
Associate Director, Clinical Research
Lombardi Comprehensive Cancer Center
Washington, DC
William K. Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director, Clinical Research
The Tisch Cancer Institute
New York, NY
Naiyer Rizvi, MD
Director, Thoracic Oncology
Director, Immunotherapeutics
Price Chair, Clinical Translational Research
Columbia University Medical Center
New York, NY
Agenda Highlights
| Wednesday, November 4, 2015 |
| Hematologic Malignancies |
| Chronic Lymphocytic Leukemia |
| Multiple Myeloma |
| Myeloproliferative Neoplasms |
| Acute Myeloid Leukemia |
| Acute Lymphoblastic Leukemia |
| Chronic Myeloid Leukemia |
| Lymphomas |
| Immunotherapy & CAR T-Cell Therapy |
| Gastrointestinal Cancers |
| Colorectal Cancer |
| Gastric Cancers |
| Hepatocellular Carcinoma |
| Pancreatic Cancer |
| Soft Tissue Sarcoma |
| Thursday, November 5, 2015 |
| Gynecologic Malignancies |
| Head and Neck Cancers |
| Oncology Informatics |
| The Future of Immuno-Oncology |
| Central Nervous System Tumors |
| Neuroendocrine Tumors |
| Chemotherapy-Induced Nausea and Vomiting |
| Breast Cancer |
| Friday, November 6, 2015 |
| Value-Based Oncology |
| Lung Cancers |
| Cutaneous Malignancies |
| Genitourinary Malignancies |
| Diverse Topics |
Click here to see the full agenda
Register
You must be logged in to PER to register for this meeting
Or Register for PER now
*Required Fields
Login Information
Registration Information
In case of onsite emergency:
Professional Information
Specialties*
Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19
I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventive measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities, including providing proof at check in of being 2 weeks removed from receiving a full COVID-19 vaccination or results from a negative COVID-19 viral test taken no more than 3 days prior to the program.
I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.
* By checking this box, you have read and understand the above and agree to its terms.
.jpg)
